MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.

Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our study found that p70S6K1 plays an important role in gemcitabine chemoresistence. MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our findings revealed a new mechanism underlying gemcitabine chemoresistance in pancreatic adenocarcinoma cells

A controllable superconducting electromechanical oscillator with a suspended membrane

We fabricate a microscale electromechanical system, in which a suspended superconducting membrane, treated as a mechanical oscillator, capacitively couples to a superconducting microwave resonator. As the microwave driving power increases, nonmonotonic dependence of the resonance frequency of the mechanical oscillator on the driving power has been observed. We also demonstrate the optical switching of the resonance frequency of the mechanical oscillator. Theoretical models for qualitative understanding of our experimental observations are presented. Our experiment may pave the way for the application of a mechanical oscillator with its resonance frequency controlled by the electromagnetic and/or optical fields, such as a microwave-optical interface and a controllable element in a superqubit-mechanical oscillator hybrid system.Comment: 8 pages,4 figure

Ethyl 2-methyl-6-(propan-2-yl­amino)-4-sulfanyl­idene-3H,11H-pyrimido[1,6-c]quinazoline-1-carboxyl­ate

The title compound, C18H22N4O2S, contains a substituted pyrimidine ring fused to both a benzene ring and a substituted thioxopyrimidine ring. The pyrimidine and thioxopyrimidine rings adopt distorted chair conformations. In the crystal, adjacent mol­ecules are linked by pairs of N—H⋯S and N—H⋯O hydrogen bonds to generate centrosymmetric R 2 2(8) and R 2 2(16) loops, respectively. This combination leads to [100] chains of mol­ecules

Three‐stage electric vehicle scheduling considering stakeholders economic inconsistency and battery degradation

This study proposes an electric vehicle (EV) aggregator operation mechanism in a residential community. The EV charging and discharging operation behaviours are scheduled to maximise the EV aggregator revenue, while EV aggregator provides reserve service for the grid. This study not only considers the energy and information interactions between three stakeholders: EV aggregator, EV owners, and power grids, but also the economic interests of aggregator and owners are considered. The aggregator-owner economic inconsistency issue (EV owners get higher charging cost in aggregator scheduling than self-scheduling) is presented. In order to mediate this issue, a rebate factor is proposed. In the first stage, the objective is to minimise the day-ahead (DA) charging cost of EV owners. Then the second stage is to maximise DA aggregator revenue with different rebate values. Finally, in the third stage, a real-time scheduling strategy is proposed to maximise aggregator revenue using the optimal rebate value. In addition, the battery degradation in influencing scheduling is formulated. Scheduling results show the effectiveness of the proposed strategy, e.g. economic inconsistency of different parties can be mediated. Significant reduction of EV owners’ cost from self-scheduling can be achieved while the revenue of EV aggregator is maximised under the proposed strategy

Characteristic analysis of α-fetoprotein-producing gastric carcinoma in China

α-Fetoprotein-producing gastric cancer (AFPGC) is a rare type of gastric cancer. The largest population of patients with AFPGC is found in China. In the present study, a total of 4,779 GC patients, including 317 AFPGC patients, from 11 clinical studies in China with a general AFPGC/GC ratio of 6.63% were summarized and analyzed. On the basis of analysis of the clinical data, the patients with AFPGC had larger tumor size, weaker cell differentiation, worse histopathological types, deeper serosal infiltration, more lymph node and liver metastases, poorer stages, shorter survival time and more positive expression of vascular endothelial growth factors than the patients without AFPGC. Our observation is consistent with previous results reported in studies of AFPGC. Overall, AFPGC is a subtype of GC with a poor prognosis